Side-by-side · Research reference

CrystagenvsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BPhase 1HUMAN-REVIEWED10/36 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Crystagen

GHRP-6

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

—

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

GHRP-6

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

100–200 mcg per injectionBowers 1990

Evidence basis

Animal / mechanistic

Phase 1 + clinical practiceBowers 1990

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

1–3× per day

Duration

Unknown — chronic administration presumed in animal models

8–12 weeks on / 4 off

Half-life

Not reported

~15 minMalagón 1999

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-meal preferred for appetite support

04Side Effects & Safety

Parameter

Crystagen

GHRP-6

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Injection site reaction

—

Mild

Cancer risk

—

Contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

Crystagen

GHRP-6

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

SQ — abdomen. Rotate sites.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

GHRP-6

— no documented stacks